Aligos Therapeutics, Inc. (NASDAQ:ALGS) Sees Significant Growth in Short Interest

Aligos Therapeutics, Inc. (NASDAQ:ALGS) was the target of a significant increase in short interest during the month of October. As of October 31st, there was short interest totalling 121,300 shares, an increase of 46.5% from the October 15th total of 82,800 shares. Based on an average trading volume of 145,700 shares, the short-interest ratio is currently 0.8 days. Approximately 4.8% of the shares of the company are short sold.

Hedge Funds Weigh In On Aligos Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of ALGS. Acadian Asset Management LLC raised its stake in Aligos Therapeutics by 17.6% during the first quarter. Acadian Asset Management LLC now owns 657,995 shares of the company’s stock worth $644,000 after acquiring an additional 98,628 shares in the last quarter. Armistice Capital LLC increased its position in shares of Aligos Therapeutics by 5.3% during the 2nd quarter. Armistice Capital LLC now owns 7,256,410 shares of the company’s stock worth $2,540,000 after purchasing an additional 363,000 shares in the last quarter. Finally, Opaleye Management Inc. increased its position in shares of Aligos Therapeutics by 25.7% during the 1st quarter. Opaleye Management Inc. now owns 1,630,000 shares of the company’s stock worth $1,597,000 after purchasing an additional 333,000 shares in the last quarter. Institutional investors own 60.43% of the company’s stock.

Wall Street Analyst Weigh In

Separately, HC Wainwright reaffirmed a “buy” rating and set a $75.00 price objective on shares of Aligos Therapeutics in a research report on Thursday, November 7th.

Aligos Therapeutics Trading Down 1.5 %

ALGS opened at $19.17 on Friday. The stock’s 50 day simple moving average is $10.26 and its 200-day simple moving average is $12.56. The stock has a market cap of $61.34 million, a PE ratio of -1.48 and a beta of 2.11. Aligos Therapeutics has a 1 year low of $6.76 and a 1 year high of $30.00.

Aligos Therapeutics (NASDAQ:ALGS) last posted its earnings results on Wednesday, November 6th. The company reported ($3.07) earnings per share for the quarter, missing analysts’ consensus estimates of ($2.15) by ($0.92). The business had revenue of $1.27 million during the quarter, compared to the consensus estimate of $1.00 million. Aligos Therapeutics had a negative net margin of 1,283.19% and a negative return on equity of 114.34%. During the same period in the previous year, the firm earned ($10.25) EPS. Equities analysts forecast that Aligos Therapeutics will post -10.36 earnings per share for the current fiscal year.

About Aligos Therapeutics

Aligos Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH).